SHANGHAI, China, Sept. 19 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics, Inc. (OTC Bulletin Board: CHBT) (''China-Biotics," "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, announced today that at its 2008 Annual General Meeting of Shareholders (the ''AGM''), stockholders re-elected all of the Company's nominees to the Board of Directors.
At the meeting, held September 12, 2008, shareholders approved the re-election of Mr. Jinan Song, Dr. Ji Wei Chin, Dr. Wen Min Du and Mr. Simon Yick as members of the Company's Board of Directors. Shareholders also ratified the appointment of BDO McCabe Lo Limited as the Company's independent auditors for the fiscal year ending March 31, 2008.
About China-Biotics, Inc.
China-Biotics, Inc. ("China-Biotics," "the Company''), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the ''Shining'' brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .
Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995: Any statements set forth above that are not historical facts
are forward-looking statements that involve risks and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements. Such factors include, but are not limited to,
the Company's ability to market existing and new products, ability to
access to capital for expansion, and changes from anticipated levels of
sales, future national or regional economic and competitive conditions,
changes in relationships with customers, dependence on its flagship product
profits and other factors detailed from time to time in the Company's
filings with the United States Securities and Exchange Commission and other
regulatory authorities. The Company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
For more information, please contact:
CCG Investor Relations
Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
|SOURCE China-Biotics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved